Abstract
Endothelin-1 (ET-1) is a peptide with various biological activities, such as vasoconstriction, mitogenesis and bronchoconstriction. It has been implicated in the pathogenesis of numerous disease processes. Suppression of the production of this peptide by inhibitors of endothelin-converting enzyme-1 (ECE-1), the key enzyme in ET-1 biosynthesis, may be a therapeutic option. There are three classes of ECE-1 inhibitors: selective ECE-1 inhibitors, dual ECE-1/neutral endopeptidase (NEP) 24.11 inhibitors and triple ECE-1/NEP/angiotensin-converting enzyme inhibitors. This review will focus briefly on the endothelin system and mainly on the ECE-1 inhibitor classes, their pharmacologic effects on animal models of various diseases and published clinical studies.
Keywords: Endothelin-1, endothelin-converting enzyme, ECE-1 inhibitors
Current Enzyme Inhibition
Title: Endothelin-Converting Enzyme Inhibitors
Volume: 2 Issue: 4
Author(s): Cristina Navarrete and Cleide Suguihara
Affiliation:
Keywords: Endothelin-1, endothelin-converting enzyme, ECE-1 inhibitors
Abstract: Endothelin-1 (ET-1) is a peptide with various biological activities, such as vasoconstriction, mitogenesis and bronchoconstriction. It has been implicated in the pathogenesis of numerous disease processes. Suppression of the production of this peptide by inhibitors of endothelin-converting enzyme-1 (ECE-1), the key enzyme in ET-1 biosynthesis, may be a therapeutic option. There are three classes of ECE-1 inhibitors: selective ECE-1 inhibitors, dual ECE-1/neutral endopeptidase (NEP) 24.11 inhibitors and triple ECE-1/NEP/angiotensin-converting enzyme inhibitors. This review will focus briefly on the endothelin system and mainly on the ECE-1 inhibitor classes, their pharmacologic effects on animal models of various diseases and published clinical studies.
Export Options
About this article
Cite this article as:
Navarrete Cristina and Suguihara Cleide, Endothelin-Converting Enzyme Inhibitors, Current Enzyme Inhibition 2006; 2 (4) . https://dx.doi.org/10.2174/157340806778699244
DOI https://dx.doi.org/10.2174/157340806778699244 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Aluminum Vaccine Adjuvants: Are they Safe?
Current Medicinal Chemistry Complement and Microglia in the Neuropathogenesis of HIV Infection: Pro- and Anti-Inflammatory Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemotherapy and Targeted Agents for Elderly Women with Advanced Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients
Current Drug Safety Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Current Drug Safety PF-04886847 (an Inhibitor of Plasma Kallikrein) Attenuates Inflammatory Mediators and Activation of Blood Coagulation in Rat Model of Lipopolysaccharide (LPS) - Induced Sepsis
Cardiovascular & Hematological Agents in Medicinal Chemistry Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
Current Clinical Pharmacology Difficulties in Describing Allergic Disease Modulation by Pre-, Pro- and Synbiotics
Current Pharmaceutical Design Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design